Skip to main content
Mo-99 Production Facility
Services

ANSTO Nuclear Medicine Project

An investment that will secure the long term sustainability of nuclear medicine supply in Australia.

What is the ANSTO Nuclear Medicine Project?

In 2012 the Australian Government announced a $168.8 million investment that will position Australia as a global leader in the manufacture of nuclear medicine and secure the long term sustainability of nuclear medicine supply in Australia.

The project includes an export scale Mo-99 Manufacturing Facility and an innovative ANSTO Synroc waste treatment plant. Both of these new facilities will be owned and operated by ANSTO Nuclear Medicine (ANM) Pty Ltd, a majority subsidiary of ANSTO.

The new Mo-99 Manufacturing Facility will enable ANSTO to triple production of Molybdenum-99 (Mo-99). The increased capacity will enable Australia to meet domestic demand, as well as being able to supply up to 25% of global demand. Used for 80 per cent of nuclear medicines, Mo-99 is the base material used in the diagnosis of cancers, heart disease, muscular and skeletal conditions.

Project timeline

Early in 2019, ANSTO's new Mo-99 Manufacturing Facility entered a 'transition phase', the final operational phase moving from sample production runs to commercial supply.

Before the facility can commence normal operation, it requires regulatory approval from both ARPANSA (from a safety perspective) and health regulators such as the TGA (from a product quality perspective).

Whilst the facility and production team are operationally ready, the various regulatory bodies have careful review processes to carry out in order to provide approval to ANM Pty Ltd for the supply of Mo-99. 

ANM was granted an operational licence by ARPANSA in August 2018, subject to the successful completion of “hot” commissioning and the fulfilment of a number of licence conditions. Whilst relevant information has been supplied to ARPANSA, we are currently in dialogue with them regarding some requests for further information. Formal approval to move into commercial operation is not expected until the end of March.

In terms of medical regulatory approval, ANM is working with both domestic and international customers to support applications to the relevant regulatory bodies which will allow supply to commence.  It is anticipated that approval will be received for domestic supply before it is received for international supply.
 

2012

The Australian Government committed $168.8 million investment for the ANM project

2013

Siting licence granted from ARPANSA

Approval granted by Department of Sustainability, Environment, Water, Population and Communities

Public Works Committee approval received

2014

 

Licence issued for construction of both the Mo-99 Manufacturing facility and the co-located ANSTO Synroc waste treatment plant

Contract to design and construct the new Mo-99 Manufacturing Facility awarded to Watpac Limited

Construction of Mo-99 Manufacturing Facility commenced

2017

Practical completion of the Mo-99 Manufacturing Facility was achieved late in 2017

2018

 

Cold commissioning successfully completed

Hot commissioning successfully completed

Construction of ANSTO Synroc waste treatment facility commenced

ARPANSA granted an operational license to the Mo-99 Manufacturing Facility late in 2018

2019

Mo-99 Manufacturing Facility moved into the ‘transition phase’ carrying out batch runs of product to support domestic and international customers in their applications to relevant regulatory bodies

Domestic commercial supply expected to commence in April - May 2019

International commercial supply expected to commence in the second half of 2019

Watch the construction stages of the Mo-99 Manufacturing Facility, part of the ANSTO Nuclear Medicine Project

 

ANM Board of Directors

The ANM Board of Directors provide governance and strategic direction for the project and work effectively with senior management to ensure the delivery of the project. The Board of Directors bring a wealth of knowledge and expertise from within the nuclear science and nuclear medicine industry.

Con Lyras_ANM Project_Board of Directors

Con Lyras, Chair 

Pamela Naidoo_ANM Project_Board of Directors

Pamela Naidoo-Ameglio,
Board Member 

Sheruna Naidoo_ANM Project_Board of Directors

Sheruna Naidoo,
Board Member 

Sarah Pearson_ANM Project_Board of Directors

Sarah Pearson,
Board Member 

Greg Santamaria_ANM Project_Board of Directors

Greg Santamaria,
Board Member